NASDAQ : PDSB
PDS Biotechnology Corporation — Key statistics
Healthcare · Biotechnology · United States
Last price 1.55 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 112.34M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 104.36M |
| Enterprise Value | 103.13M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 72.47M |
| Shares Outstanding | 72.47M |
| Shares Change (YoY) | +30.89% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 1.95% |
| Owned by Institutions (%) | 10.99% |
| Float | 58.06M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.57 |
| Quick Ratio | 0.45 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.18 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -543.97% |
| Return on Assets (ROA) | -70.59% |
| Return on Invested Capital (ROIC) | -98.61% |
| Return on Capital Employed (ROCE) | 779.57% |
| Weighted Average Cost of Capital (WACC) | 15.08% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.60M |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.17 |
| 52-Week Price Change | +42.57% |
| 50-Day Moving Average | 0.80 |
| 200-Day Moving Average | 0.83 |
| Relative Strength Index (RSI) | 60.13 |
| Average Volume (20 Days) | 12,914,102 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.39M |
| Short Previous Month | 2.77M |
| Short % of Shares Out | 4.67% |
| Short % of Float | 5.83% |
| Short Ratio (days to cover) | 0.09 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -27.83M |
| Pretax Income | -33.67M |
| Net Income | -33.67M |
| EBITDA | -27.77M |
| EBIT | -27.83M |
| Earnings Per Share (EPS) | -$0.64 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 5.60M |
| Total Debt | 4.36M |
| Net Cash | 1.23M |
| Net Cash Per Share | $0.02 |
| Equity (Book Value) | -3.58M |
| Book Value Per Share | -0.06 |
| Working Capital | -5.33M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -16.78M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 60,518 |
| Net Borrowing | -19.90M |
| Free Cash Flow | -16.78M |
| FCF Per Share | -$0.23 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -30.89% |
| Shareholder Yield | -30.89% |
| Earnings Yield | -44.45% |
| FCF Yield | -16.08% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $4.50 |
| Price Target Difference | 212.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Mar 18, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |